Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping |
| |
Authors: | Richardson Christine M Nunns Claire L Williamson Douglas S Parratt Martin J Dokurno Pawel Howes Rob Borgognoni Jenifer Drysdale Martin J Finch Harry Hubbard Roderick E Jackson Philip S Kierstan Peter Lentzen Georg Moore Jonathan D Murray James B Simmonite Heather Surgenor Allan E Torrance Christopher J |
| |
Affiliation: | Vernalis (R&D) Ltd, Granta Park, Cambridge CB21 6GB, UK. c.richardson@vernalis.com |
| |
Abstract: | Virtual screening against a pCDK2/cyclin A crystal structure led to the identification of a potent and novel CDK2 inhibitor, which exhibited an unusual mode of interaction with the kinase binding motif. With the aid of X-ray crystallography and modelling, a medicinal chemistry strategy was implemented to probe the interactions seen in the crystal structure and to establish SAR. A fragment-based approach was also considered but a different, more conventional, binding mode was observed. Compound selectivity against GSK-3beta was improved using a rational design strategy, with crystallographic verification of the CDK2 binding mode. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|